
Double-chamber cartridge
The dry research compound and sterile water are sealed in separate chambers, avoiding a pre-mixed liquid during storage and transport.
Research compound · 20 mg
A focused research presentation from J-Pep Labs, with clear product information and direct access to independent batch documentation.
For laboratory research use only. Not for human consumption or medical use.

About the compound
Retatrutide, also known by the clinical-development code LY3437943, is an investigational peptide designed as a triple agonist at the GIP, GLP-1 and glucagon receptors.
J-Pep Labs focuses on 20 mg lyophilized research presentations, including the standard vial and a convenient double-chamber cartridge format. This website provides product facts, scientific context, batch-documentation access and a direct contact channel.
A more convenient format
J-Pep Labs is helping lead the move toward a double-chamber cartridge presentation: lyophilized Retatrutide remains physically separate from sterile water until the system is activated.

The dry research compound and sterile water are sealed in separate chambers, avoiding a pre-mixed liquid during storage and transport.

The self-contained pen provides a clean, compact way to activate the cartridge, prepare the solution and dispense it for the intended research workflow.
How it works
Storage Note: Keep dry until ready for use—no refrigeration required prior to mixing. Once reconstituted/mixed, store in the refrigerator.
Research preparation tool
Enter the peptide amount, sterile water, dosage and syringe size to calculate the exact unit mark, concentration, volume per dose and doses per vial.
Calculation tool only. This tool converts values you enter and does not recommend a dosage, route or frequency.
Draw to
Select a syringe size
Enter the vial amount, water, dosage and syringe size to see the result.
Confirm all entered values and calculations independently. Follow the supplied product handling, storage and research instructions.
Why it is being studied
Retatrutide remains investigational. The points below summarize scientific interest and published trial findings; they are not claims about the J-Pep Labs vial and are not medical advice.
Retatrutide is a single investigational molecule designed to activate GIP, GLP-1 and glucagon receptors.
The three-pathway mechanism is being studied for its effects on appetite, energy balance and metabolic markers.
A phase 2 obesity trial reported dose-dependent body-weight reduction over 48 weeks, supporting continued clinical research.
Independent batch documentation
Review the Janoshik reports for this Retatrutide 20 mg batch. Each button opens the original report directly on Janoshik's verification website.
Review the independent analytical report for the tested sample, including the measurements listed by Janoshik.
Open COA on Janoshik ↗Open the independent Janoshik endotoxin test for this Retatrutide batch and review the original laboratory report.
Open endotoxin test ↗Important: Each laboratory report applies only to the tested sample and its listed test scope. An endotoxin result is not the same as a sterility test, and these reports do not approve a product for human use.
Contact J-Pep Labs
Send your enquiry directly from this page. It will arrive at info@j-peplabs.com, and we can reply to the email address you provide.